Barclays analyst Gena Wang upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Underweight to Equalweight with a price target of $22.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE